TD Asset Management Inc Sells 64,456 Shares of Moderna, Inc. $MRNA

TD Asset Management Inc decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 51.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,813 shares of the company’s stock after selling 64,456 shares during the period. TD Asset Management Inc’s holdings in Moderna were worth $1,705,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new position in Moderna during the first quarter valued at approximately $25,000. TD Private Client Wealth LLC lifted its position in Moderna by 348.8% during the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock valued at $26,000 after purchasing an additional 743 shares during the period. SVB Wealth LLC bought a new position in Moderna during the first quarter valued at approximately $28,000. CX Institutional lifted its position in Moderna by 1,129.8% during the second quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after purchasing an additional 949 shares during the period. Finally, Costello Asset Management INC bought a new position in Moderna during the first quarter valued at approximately $30,000. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Up 0.9%

Shares of NASDAQ MRNA opened at $27.49 on Wednesday. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $57.69. The company has a 50 day simple moving average of $25.98 and a two-hundred day simple moving average of $27.12. The stock has a market cap of $10.74 billion, a price-to-earnings ratio of -3.65 and a beta of 2.01.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business had revenue of $142.00 million during the quarter, compared to analysts’ expectations of $116.26 million. During the same period in the previous year, the business posted ($3.33) EPS. The business’s quarterly revenue was down 41.1% compared to the same quarter last year. Moderna has set its FY 2025 guidance at EPS. Analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of analyst reports. Bank of America cut their price objective on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating on the stock in a research report on Tuesday, July 22nd. Leerink Partners cut their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. Evercore ISI set a $32.00 price objective on shares of Moderna in a research report on Friday, August 1st. Morgan Stanley boosted their target price on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Finally, Cowen initiated coverage on shares of Moderna in a research report on Sunday, July 13th. They set a “hold” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $39.93.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.